Foghorn Therapeutics (FHTX) Interest Expenses (2019 - 2021)

Foghorn Therapeutics' Interest Expenses history runs 8 years deep, the most recent figure standing at $60.8 million for Q1 2026.

• In Q1 2026, Interest Expenses rose 2101.7% year-over-year to $60.8 million; the TTM figure through Mar 2026 stood at $60.8 million (up 1114.76% YoY), while the FY2025 annual figure was $187.6 million, up 12.74% from the prior year.
• Interest Expenses for Q1 2026 stood at $60.8 million, up from $1.7 million in the prior quarter.
• The five-year high for Interest Expenses was $143.0 million in Q4 2023, with the low at -$7.7 million in Q4 2024.
• The 5-year median for Interest Expenses is $2.7 million (2023), against an average of $20.4 million.
• The sharpest annual moves came in 2024 and 2025: Interest Expenses tumbled 105.42% in 2024, then surged 101028.0% in 2025.
• Foghorn Therapeutics' Interest Expenses stood at $10.0 million in 2022, then surged by 1331.67% to $143.0 million in 2023, then sank by 105.42% to -$7.7 million in 2024, then jumped by 121.74% to $1.7 million in 2025, then jumped by 3513.25% to $60.8 million in 2026.
• Business Quant data shows FHTX's Interest Expenses at $60.8 million in Q1 2026, $1.7 million in Q4 2025, and $25.3 million in Q3 2025.